Infection prevention in the cancer center

Clinical Infectious Diseases

Volumn 57, Issue 4, 2013, Pages 579-585

  Thom, Kerri A ^a   Kleinberg, Michael ^a   Roghmann, Mary Claire ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer center; Immune suppressed; Infection prevention

Indexed keywords

CHLORHEXIDINE; QUINOLONE DERIVATIVE; VACCINE;

ANTIBIOTIC PROPHYLAXIS; BLOODSTREAM INFECTION; CANCER CENTER; CANCER PATIENT; CATHETER COMPLICATION; DEVICE INFECTION; DIET; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DISINFECTION; HEALTH CARE PERSONNEL; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTRAVASCULAR CATHETER; LUNG ASPERGILLOSIS; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OUTPATIENT; PERSONAL HYGIENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; URINARY TRACT INFECTION; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION;

CANCER CENTER; IMMUNE SUPPRESSED; INFECTION PREVENTION;

COMMUNICABLE DISEASES; CROSS INFECTION; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION CONTROL; NEOPLASMS;

EID: 84880947660     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit290     Document Type: Review

References (50)

1. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143-238.
2. Climo MW, Sepkowitz KA, Zuccotti G, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009; 37:1858-65.
3. Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013; 368: 533-42.
4. Epstein JB, Stevenson-Moore P. Periodontal disease and periodontal management in patients with cancer. Oral Oncol 2001; 37:613-9.
5. International Bottled Water Association. Available at: http://www.bottledwater.org/. Accessed 18 March 2013.
6. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353:977-87.
7. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a metaanalysis. Clin Infect Dis 1996; 23:795-805.
8. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16:1179-87.
9. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142(12 Pt 1):979-95.
10. van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: A systematic review of randomised controlled trials. Eur J Cancer 2005; 41:1372-82.
11. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:427-31.
12. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24:111-8.
13. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-60.
14. Mollee P, Jones M, Stackelroth J, et al. Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study. J Hosp Infect 2011; 78:26-30.
15. O'Grady NP, Alexander M, Burns LA, et al. Summary of recommendations: guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52:1087-99.
16. Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA, Healthcare Infection Control Practices Advisory Committee. Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol 2010; 31:319-26.
17. Shah DP, Ghantoji SS, Mulanovich VE, Ariza-Heredia EJ, Chemaly RF. Management of respiratory viral infections in hematopoietic cell transplant recipients. Am J Blood Res 2012; 2:203-18.
18. Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med 1997; 102:10-8; discussion 25-6.
19. Murali S, Langston AA, Nolte FS, Banks G, Martin R, Caliendo AM. Detection of respiratory viruses with a multiplex polymerase chain reaction assay (Multi Code-PLx respiratory virus panel) in patients with hematologic malignancies. Leuk Lymphoma 2009; 50:619-24.
20. Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 32:1085-8.
21. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13:371-84.
22. Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am J Med 1997; 102(3A):55-60; discussion 75-6.
23. Henrickson KJ. Human parainfluenza viruses. In: Gorbach SL, Bartlett JG, Blacklow NR. Infectious diseases. 3rd ed. Philadelphia, PA: Lippincott, Williams &Wilkins, 2003; 1997-2015.
24. Garner JS. Guideline for isolation precautions in hospitals.: the hospital infection control practices advisory committee. Infect Control Hosp Epidemiol 1996; 17:53-80.
25. Siegel JD, Rhinehart E, Jackson M, Chiarello L, Health Care Infection Control Practices Advisory Committee. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007; 35(10 suppl 2):S65-164.
26. Bolyard EA, Tablan OC, Williams WW, Pearson ML, Shapiro CN, Deitchmann SD. Guideline for infection control in healthcare personnel, 1998. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol 1998; 19:407-63.
27. Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the healthcare infection control practices advisory committee. MMWR Recomm Rep 2004; 53(RR-3):1-36.
28. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100:345-51.
29. Allam MF, Del Castillo AS, Diaz-Molina C, Navajas RF. Invasive pulmonary aspergillosis: identification of risk factors. Scand J Infect Dis 2002; 34:819-22.
30. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) alliance registry. Clin Infect Dis 2009; 48:265-73.
31. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. disease spectrum, treatment practices, and outcomes. I3 aspergillus study group. Medicine (Baltimore) 2000; 79:250-60.
32. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91:1068-75.
33. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23-32.
34. Hahn-Ast C, Glasmacher A, Muckter S, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 2010; 65:761-8.
35. Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial aspergillus infections. unique risk of bone marrow transplant recipients. Am J Med 1987; 83:709-18.
36. Rhame FS. Nosocomial aspergillosis: how much protection for which patients? Infect Control Hosp Epidemiol 1989; 10:296-8.
37. Hahn T, Cummings KM, Michalek AM, Lipman BJ, Segal BH, McCarthy PL Jr. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol 2002; 23:525-31.
38. Vonberg RP, Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect 2006; 63:246-54.
39. Szyper-Kravitz M, Lang R, Manor Y, Lahav M. Early invasive pulmonary aspergillosis in a leukemia patient linked to Aspergillus contaminated marijuana smoking. Leuk Lymphoma 2001; 42:1433-7.
40. Cescon DW, Page AV, Richardson S, Moore MJ, Boerner S, Gold WL. Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. J Clin Oncol 2008; 26:2214-5.
41. Centers for Disease Control and Prevention. Guidance for control of carbapenem-resistant Enterobacteriaceae (CRE), 2012 CRE toolkit. Available at: http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf. Accessed 18 March 2013.
42. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60(RR-7):1-45.
43. Prevots DR, Burr RK, Sutter RW, Murphy TV, Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR-5):1-22. ; quiz CE1-7.
44. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47(RR-8):1-57.
45. Pearson ML, Bridges CB, Harper SA, Healthcare Infection Control Practices Advisory Committee (HICPAC), Advisory Committee on Immunization Practices (ACIP). Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-2): 1-16.
46. Advisory Committee on Immunization Practices Smith NM, Bresee JS, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-10):1-42.
47. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, doubleblind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006; 25:590-5.
48. Centers for Disease Control and Prevention. Herpes zoster vaccination for health care professionals. Available at: http://www.cdc.gov/vaccines/vpd-vac/ shingles/hcp-vaccination.htm. Accessed 18 March 2013.
49. Halpern MT, Yabroff KR. Prevalence of outpatient cancer treatment in the United States: estimates from the medical panel expenditures survey (MEPS). Cancer Invest 2008; 26:647-51.
50. Centers for Disease Control and Prevention. Basic infection control and prevention plan for outpatient oncology settings. Available at: http://www.cdc.gov/hai/pdfs/guidelines/basic-infection-control-preventionplan- 2011.pdf. Accessed 18 March 2013.